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Ketogenic diet attenuates 
hepatopathy in mouse model 
of respiratory chain complex 
III deficiency caused by a Bcs1l 
mutation
Janne Purhonen1,2, Jayasimman Rajendran  1,2, Matthias Mörgelin3, Kristiina Uusi-Rauva1, 
Shintaro Katayama4, Kaarel Krjutskov1,4,5,7, Elisabet Einarsdottir  1,4,7, Vidya Velagapudi6, 
Juha Kere  1,4,7,8, Matti Jauhiainen9, Vineta Fellman1,10,11 & Jukka Kallijärvi  1
Mitochondrial disorders are among the most prevalent inborn errors of metabolism but largely lack 
treatments and have poor outcomes. High-fat, low-carbohydrate ketogenic diets (KDs) have shown 
beneficial effects in mouse models of mitochondrial myopathies, with induction of mitochondrial 
biogenesis as the suggested main mechanism. We fed KD to mice with respiratory chain complex III 
(CIII) deficiency and progressive hepatopathy due to mutated BCS1L, a CIII assembly factor. The mutant 
mice became persistently ketotic and tolerated the KD for up to 11 weeks. Liver disease progression 
was attenuated by KD as shown by delayed fibrosis, reduced cell death, inhibition of hepatic progenitor 
cell response and stellate cell activation, and normalization of liver enzyme activities. Despite no clear 
signs of increased mitochondrial biogenesis in the liver, CIII assembly and activity were improved and 
mitochondrial morphology in hepatocytes normalized. Induction of hepatic glutathione transferase 
genes and elevated total glutathione level were normalized by KD. Histological findings and 
transcriptome changes indicated modulation of liver macrophage populations by the mutation and 
the diet. These results reveal a striking beneficial hepatic response to KD in mice with mitochondrial 
hepatopathy and warrant further investigations of dietary modification in the management of these 
conditions in patients.
Mitochondrial disorders can manifest as hepatopathy, mainly in infants, with or without other organ manifestations1. 
Only supportive treatments, such as adjustment of nutrition and vitamin supplementation to alleviate the meta-
bolic imbalance, are available for these patients1, 2.
Mutations in the BCS1L gene, encoding a CIII assembly factor, are the most common diagnosed cause of 
mitochondrial respiratory chain (RC) CIII (CIII) deficiency3. GRACILE syndrome4 (fetal growth restriction, 
aminoaciduria, cholestasis, liver iron overload, lactic acidosis, and early death during infancy) is caused by a 
homozygous missense mutation (c.232 A > G, p.S78G) in BCS1L5. In liver mitochondria of the patients, Rieske 
iron-sulfur protein (RISP, UQCRFS1) incorporation into CIII is decreased resulting in reduced CIII activity6. 
We have generated a viable mouse model of CIII dysfunction by introducing the Bcs1lc.232A>G mutation into the 
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mouse genome7. The homozygous mice display growth failure, low blood glucose, high blood lactate and progres-
sive hepatopathy from the fourth week of age, recapitulating many of the main findings in the patients.
Carbohydrate-restricted high-fat ketogenic diets stimulate mitochondrial β-oxidation and ketone body pro-
duction in the liver8, 9. Ketone bodies can be utilized as an alternative energy source by the brain, heart and 
skeletal muscle. KDs are an established therapy in drug-resistant epilepsies and have been shown to increase the 
expression of genes related to tricarboxylic acid cycle and RC function, as well as the number of mitochondria 
in rat hippocampi8–10. KDs have been proposed and tested as a therapy for mitochondrial disorders. Krebs et al. 
hypothesized that the course of postweaning-onset mitochondrial cardiomyopathy in Med30 mutant mice is 
affected by the considerable decrease in fat intake on shifting from maternal milk (42% fat) to the low-fat regular 
chow. Indeed, the researchers could extend the survival of the mutant mice by 40% by weaning them to high-fat 
ketogenic diet11. Schiff et al. showed that high-fat diet-fed Harlequin mice with CI deficiency exhibit a slower 
progression of the neurodegenerative phenotype12. In a mouse model of late-onset mitochondrial myopathy, KD 
decreased the amount of cytochrome c oxidase negative muscle fibers and prevented mitochondrial ultrastruc-
tural abnormalities in the muscle and normalized metabolic and lipidomic changes13. In a subsequent study by 
this group a modified Atkins diet caused muscle pain in the myopathy patients and selective lysis of abnormal 
muscle fibers, which was considered eventually beneficial for the muscle function14. Moreover, KD has been 
shown to increase mitochondrial mass in skeletal muscle13, heart15 and brown adipose tissue16.
With the hypothesis that KD may induce mitochondrial biogenesis to compensate reduced RC function, 
improve energy metabolism and ameliorate disease progression, we performed a dietary intervention to assess 
the effect of KD on liver disease in the Bcs1l mutant model of CIII dysfunction.
Results
KD induces persistent ketosis in Bcs1l mutant (Bcs1lG/G) mice. KD was fed to cohorts of mutant 
mice and wild-type (WT) littermates starting from weaning. To monitor ketosis in the feeding cohorts, blood 
β-hydroxybutyrate levels were measured at the time of sacrificing. WT mice on KD had significantly elevated 
β-hydroxybutyrate levels at P45, but after that the ketogenic effect decreased (Table 1). In contrast, the KD-fed 
Bcs1lG/G mice were ketotic during the entire intervention. Non-fasting blood glucose level of Bcs1lG/G mice was 
lower than in WT animals but similar on both diets. Plasma creatinine, urea and total protein were normal 
(Table 1). KD did not influence weight gain in either genotype (Supplementary Fig. 1). Bcs1lG/G mice tolerated KD 
from weaning for up to two and half months and thereafter showed behavioral decline suggesting adverse effect 
of the diet (data not shown).
KD delays liver fibrosis and inhibits stellate cell activation and hepatic progenitor cell response 
in Bcs1lG/G mice. In WT mice, KD had a minimal effect on liver histology (Fig. 1A) but caused a mod-
est increase in liver triglyceride amount (Fig. 1C,F) and reduced liver glycogen content (Supplementary Fig. 2). 
Non-esterified fatty acid concentration was similar in all groups (Supplementary Fig. 3). Bcs1lG/G mice on control 
diet (CD) had early-stage hepatopathy characterized by expansion of portal triads with incipient fibrosis at P45 
(Fig. 1A). Marked hepatocyte hypertrophy was observed centrivenously and to some degree throughout the lob-
ules (Supplementary Fig. 4B,C). Apoptotic cells, single necrotic cells (Fig. 1E) and mitotic figures were frequent. 
Staining for the mitotic cell marker Ki-67 confirmed a proliferative response at P45, which tended to resolve by 
Age 
(d)
WT Bcs1lG/G
CD KD CD KD
Whole blood
Glucose (mmol/L)
45 8.1 ± 1.3 (7) 8.3 ± 1.3 (7) 5.6 ± 2.0††† (9) 5.0 ± 1.9 (7)
95 8.9 ± 1.6 (8) 10.3 ± 2.0 (9) 4.7 ± 1.1††† (8) 3.2 ± 1.1 (6)
Lactate (mmol/L)
45 3.2 ± 1.9 (9) 2.7 ± 2.4 (7) 5.0 ± 4.6 (9) 3.1 ± 2.8 (8)
95 8.8 ± 2.0 (8) 4.3 ± 2.3 (9) 6.5 ± 3.6 (8) 8.1 ± 3.4 (6)
Lactate to glucose ratio
45 0.36 ± 0.22 (7) 0.36 ± 0.32 (6) 0.90 ± 0.84 (8) 0.67 ± 0.68 (7)
95 0.8 ± 0.3 (8) 0.4 ± 0.3 (9) 1.3 ± 0.6† (8) 2.3 ± 0.9‡‡ (6)
β-hydroxybutyrate (mmol/L)
45 0.36 ± 0.3 (6) 2.0 ± 0.6*** (3) 0.58 ± 0.2 (4) 4.8 ± 1.1‡‡‡ (3)
95 0.58 ± 0.2 (8) 0.67 ± 0.2 (9) 0.87 ± 0.4 (8) 4.9 ± 2.0‡‡ (6)
Plasma all 95
Alanine aminotransferase (U/L) 42 ± 8 (5) 88 ± 67 (5) 260 ± 75††† (5) 170 ± 71 (5)
Alkaline phosphatase (U/L) 57 ± 19 (5) 30 ± 23 (5) 190 ± 56††† (5) 80 ± 40‡ (5)
Creatinine (µmol/L) 16 ± 4 (5) 17 ± 3 (5) 20 ± 3 (5) 28 ± 6 (5)
Urea (mmol/L) 8.3 ± 1.3 (5) 6.5 ± 0.9 (5) 8.5 ± 0,6 (5) 6.8 ± 2.4 (5)
Uric acid (µmol/L) 75 ± 33 (5) 51 ± 20 (5) 140 ± 35† (5) 160 ± 110 (5)
Total protein (g/L) 49 ± 2 (5) 53 ± 4 (5) 46 ± 5 (5) 52 ± 5 (5)
Table 1. Biochemical parameters in whole blood and plasma, mean ± SD (n). Non-fasting blood samples were 
used for the measurements. Significances p < 0.05, < 0.01 and < 0.001 are indicated for comparisons between 
WT on CD vs WT on KD (*, ** and ***), WT on CD vs Bcs1lG/G on CD (†, ††, †††) and Bcs1lG/G on CD vs 
Bcs1lG/G on KD (‡, ‡‡, ‡‡‡), respectively. n numbers in brackets.
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Figure 1. Ketogenic diet modulates hepatopathy progression in Bcs1lG/G mice. (A) Representative H&E stained 
liver sections showing ductular reactions (yellow arrows) and portal inflammation (green arrow) in the Bcs1lG/G 
mice on control diet (CD). The ketogenic diet (KD) normalized the expansion of portal areas at postnatal day 45 
(P45). A partial amelioration was also observed at postnatal day 95 (P95). For higher-magnification images and 
their description see Supplementary Fig. 3. (B) Sirius Red staining of liver collagen showing incipient fibrosis 
at P45 and marked periportal and sinusoidal fibrosis at P95 in the Bcs1lG/G mice on CD. (C) Oil Red O staining 
of liver cryosections to show neutral lipid accumulation. (D) Quantification of fibrosis from Sirius Red-stained 
liver sections showing delayed fibrosis in the Bcs1lG/G mice on KD. n = 5–8/group for Bcs1lG/G mice (both 
time points) and 3–4/group for WT mice at P45 and 8–9 /group at P95, respectively. **p < 0.01, ***p < 0.001 
(two-way ANOVA with age group as a factor to be controlled) (E) Count of apoptotic and necrotic cells in 
H&E-stained liver sections. ***p < 0.001 (Mann-Whitney U-test) (F) Liver triglyceride assay. ***p = 0.0001 
for the diet effect, * p = 0.44 for diet*age interaction (two-way ANOVA). n = 7–13/group. The error bars stand 
for standard deviation. Abbreviations: WT, wild-type mice; Bcs1lG/G, mice homozygous for the Bcs1lc.232A>G 
knock-in mutation.
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P95 (Supplementary Fig. 5). Collagen staining showed periportal fibrosis at P45 (Fig. 1B) and at P95 prominent 
pericellular fibrosis was also observed. Occasionally fibrotic septa connected two or more portal triads. Highly 
increased α-smooth muscle actin (α-SMA) immunostaining indicated stellate cell activation (Fig. 2A,B).
KD modulated progression of the hepatopathy in several ways (Figs 1 and 2): it reduced the number of apop-
totic and necrotic cells, prevented expansion of portal areas and delayed progression of fibrosis (Fig. 1) and dimin-
ished liver glycogen content (Supplementary Fig. 2). The expansion of portal areas resembled hepatic progenitor 
cell response (ductular reactions and oval cell hyperplasia)17 (Fig. 1A and Supplementary Fig. 4D). Accordingly, 
immunostaining revealed aberrant expression of cytokeratin-7, a marker of bile ducts and hepatic progenitor 
cells (oval cells), mainly periportally but also across the parenchyma (Fig. 2A,C). The aberrant cytokeratin-7 
expression was completely normalized by KD at P45 and attenuated at P95 (Fig. 2A,C). Also plasma alanine 
aminotransferase and alkaline phosphatase activities were reduced by KD (Table 1). Further details of the liver 
histology are shown in Supplementary Fig. 4.
KD normalizes the ultrastructure of hepatocyte mitochondria and improves CIII assembly and 
activity in Bcs1lG/G livers. Electron microscopy showed that in hepatocyte mitochondria of Bcs1lG/G mice 
the number of cristae was reduced and thickness increased as compared to WT mice (Fig. 3A–C). Both param-
eters were normalized in the KD-fed mice at all time points (P45-P171). The proportion of elongated mitochon-
dria was increased by the mutation, KD and age of the mice (Fig. 3D). The elongated mitochondria in KD-fed 
Bcs1lG/G mice had also a larger cross-sectional area than the mitochondria in the mutant mice on CD (Fig. 3D).
Of the two main markers of mitochondrial mass, mtDNA copy number was unchanged between the groups 
(Fig. 4A), whereas citrate synthase (CS) activity was increased in Bcs1lG/G livers but not affected by KD (Fig. 4B). 
Western blot analysis of Bcs1lG/G liver lysates revealed, as expected7, reduced level of RISP and a similar amount 
of the earlier assembled CIII subunit CORE-1 as compared to WT lysates (Fig. 4C). The amount of neither 
CIII subunit was affected by KD in total liver lysates. VDAC1, a mitochondrial protein not part of the RC, was 
increased in liver lysates of the Bcs1lG/G mice on CD, as were also subunits of CI (NDUFA9) and CIV (COX1, 
cytochrome c oxidase I, MT-CO1). The level of these proteins was normalized by KD (Fig. 4C). CIII activity 
in isolated Bcs1lG/G liver mitochondria was reduced by approximately 70% on normal diet. KD increased CIII 
activity approximately 50% in both genotypes (Fig. 4D). Blue native gel electrophoresis (BNGE) and subsequent 
immunoblotting of intact complexes in isolated liver mitochondria showed that the amount of RISP in free CIII 
dimer and, in particular, in the fully assembled CI-CIII supercomplex was significantly increased in the mutant 
mice on KD as compared to CD (Fig. 4E). Free CI was abundant only in the mutant mice but normal levels of 
supercomplex-bound CI were observed. No gross differences were found in the amount of CII and CIV between 
the groups (Fig. 4E).
In skeletal muscle, CS activity was significantly increased by KD in both genotypes and RISP amount reduced 
in the mutant mice, but none of the RC complex subunits analyzed were changed (Supplementary Fig. 6). In 
brown adipose tissue, RISP level was reduced in the mutant mice but neither CS, RC subunits nor uncoupling 
protein 1 (UCP1) were changed (Supplementary Fig. 7).
Liver transcriptome changes reflect regenerative response, activated lysosomal function and 
upregulation of tricarboxylic acid cycle in early symptomatic (P40-45) Bcs1lG/G mice. Principal 
component analysis (Fig. 5A), profiles of differentially expressed genes (Fig. 5B) and pathway analyses 
(Supplementary Table 1) demonstrated that of the examined conditions the mutation had the greatest effect on 
the liver transcriptome (1200 differentially expressed genes). KD changed the expression of approximately 260 
genes in WT mice and 460 genes in Bcs1lG/G mice. The largest block of up-regulated genes in Bcs1lG/G mice was 
related to translation and ribosomes (Fig. 5B,C and Supplementary Table 1), likely reflecting the regenerative 
response. Lysosome-related genes were also overrepresented among the up-regulated genes in Bcs1lG/G livers. The 
genes with the highest differential expression are listed in Supplementary Table 2.
The levels of transcripts encoding RC components were mostly unaltered between the groups (Supplementary 
Fig. 8). An exception was Uqrcb encoding a CIII subunit which was up-regulated 3.7-fold by KD in both geno-
types (p < 0.0001). Of mitochondria-related genes, the majority of tricarboxylic acid cycle genes were induced 
by both the mutation and the diet (Fig. 4I). The hepatic expression of two circulating mitochondrial disease 
markers, Fgf2118 and Gdf1519 was up-regulated in Bcs1lG/G mice and Gdf15 expression was normalized by KD 
(Fig. 4H). Upstream regulatory analysis predicted that KD activated peroxisome proliferator-activated receptors 
(PPAR-α,-γ and -α), TFAM and PGC-1α and inhibited CREB, all transcriptional regulators of mitochondrial 
biogenesis (Fig. 5D). The observed mRNA level of Ppargc1a (PGC-1α) was increased in the Bcs1lG/G mice but not 
affected by the diet (Fig. 4G). Expression of a recently identified mitophagy and mitochondrial mass regulator 
Bnip320 was increased 1.4-fold (p = 0.02) and 1.8-fold (p < 0.001) by KD in WT mice and Bcs1lG/G mice, respec-
tively. Bcs1lG/G mice on CD had decreased (-1.6-fold) expression of Bnip3 and related autophagy regulators, Atg3 
(−1.8-fold) and Atg5 (−1.5-fold) compared to WT mice on CD (all p < 0.001).
Amino acid and lipid metabolism are altered at transcriptome and metabolite levels in Bcs1lG/G 
mice. The expression of multiple amino acid starvation response genes (i.e. Atf3, Atf4, Ddit3, Trib3, Asns and 
Txnip) was up-regulated in Bcs1lG/G mice (Supplementary Fig. 9). Amino acid metabolism-related genes were 
enriched in all comparisons (Fig. 5B,C and Supplementary Fig. 10A). Targeted plasma metabolomics revealed 
elevated concentrations of eight amino acids in the Bcs1lG/G mice (Supplementary Fig. 10B). In line with a prob-
able increase in protein catabolism, gene expression pathway analyses predicted altered urea cycle activity in 
Bcs1lG/G livers (Fig. 5B,C), and, accordingly, the plasma level of arginine was decreased and ornithine and citrul-
line increased (Supplementary Fig. 10B).
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Figure 2. Ketogenic diet modulates activation of hepatic progenitor cells, stellate cells and liver macrophages 
in Bcs1lG/G mice. (A) Immunostainings of liver sections for hepatic progenitor cell and bile duct marker 
cytokeratin-7; activated stellate cell marker α-smooth muscle actin (α-SMA) and macrophage markers F4/80 
and IBA1. (A,B) In wild-type livers α-SMA staining (dark blue) is seen only in the smooth muscle layer of 
arterioles but in the Bcs1lG/G mice on CD staining appears in numerous activated spindle-like stellate cells. In 
the Bcs1lG/G mice on KD the stellate cell α-SMA signal is diminished. (A, C) In wild-type livers cytokeratin-7 
staining (dark brown) is only seen in bile ducts whereas in Bcs1lG/G livers the staining is present in numerous 
cells in the liver parenchyma. The abnormal staining is almost completely absent in the Bcs1lG/G mice on KD 
at P45. (A,D,E) F4/80 and IBA1 stainings (dark brown) show normal Kupffer cells in wild-type livers. IBA1 
staining is increased in Bcs1lG/G livers but normalized by KD. Characteristic IBA1-positive macrophages 
surrounding a hepatocyte (crown-like structure, arrow) in Bcs1lG/G mice. All scale bars present 100 μm. 
**p < 0.01; ***p < 0.001.
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Figure 3. Ultrastructure of hepatocyte mitochondria is modulated by the Bcs1l mutation and the diet. (A) 
Upper row of representative electron micrographs shows general mitochondrial morphology in hepatocytes and 
lower panel typical cristae morphology and number of cristae in wild-type and Bcs1lG/G mice on CD and KD. 
(B-C) Mean mitochondrion cristae number and thickness. The data points represent five hundred mitochondria 
per mouse (mean ± SD). (D) Quantification of elongated and roundish mitochondria. Statistics: 1-way ANOVA 
followed by planned comparisons for all parameters except for cristae thickness for which Kruskal-Wallis test 
followed by Mann-Whitney U-tests was used. p < 0.05, p < 0.01, p < 0.001 (*, ** and *** vs WT CD), (†, †† and 
††† vs WT CD), (‡, ‡‡ and ‡‡‡ vs Bcs1lG/G CD).
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Figure 4. Ketogenic diet improves CIII assembly and activity but does not increase mitochondrial mass in 
Bcs1lG/G livers. (A) Liver mitochondrial DNA (mtDNA) relative to nuclear DNA. (B) Citrate synthase activity in 
liver lysate as a marker of mitochondria content. (C) Western blot analysis of RC proteins and VDAC1 (PORIN) 
in liver lysates. The data were normalized to total protein transferred to membrane as quantified from total 
protein staining. (D) Spectrophotometric analysis of CIII activity in isolated liver mitochondria. (E) Blue native 
polyacrylamide gel electrophoresis of digitonin-solubilized mitochondria and subsequent Western blot and 
analysis of intact RC complexes and supercomplexes (SC). (F) Quantification of RISP amount in CIII dimer 
(CIII2) and in supercomplex containing CI and CIII2. The band intensities were normalized to CIII subunit 
CORE-1. (G) Relative expression of Ppargc1a, a master regulator of mitochondrial biogenesis. (H) Hepatic 
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Gene expression pathway analyses further suggested that hepatic lipid metabolism was profoundly altered 
by the mutation and the diet (Fig. 5B,C, Supplementary Fig. 11A and Supplementary Table 1). The expression 
of genes related to ketone body synthesis, bile acid biosynthesis and ω-3 and ω-6 fatty acid metabolism were 
up-regulated by KD (Fig. 5B,C). Several bile acid biosynthesis-related genes were down-regulated in Bcs1lG/G 
mice (Fig. 5B,C). Metabolomics analysis showed increased plasma concentrations of cholic acid and chenode-
oxycholic (Supplementary Fig. 11B). Also, the concentrations of plasma carnitine and short-chain acylcarnitines 
were decreased by the mutation and KD further indicating altered lipid metabolism (Supplementary Fig. 11B).
KD modulates altered hepatic macrophage populations in Bcs1lG/G mice. In H&E-stained liver 
sections of Bcs1lG/G mice, cells with brownish cytoplasm and morphologically resembling macrophages were 
observed (Supplementary Fig. 12). These cells were PAS-diastase-positive and auto-fluorescent (Supplementary 
Fig. 12), suggesting that they were ceroid- or lipofuscin-laden macrophages. The number of these cells was 
decreased by KD. Immunostaining for macrophage/Kupffer cell markers showed similar number of hepatic mac-
rophages with both F4/80 and IBA1 antibodies in WT mice (Fig. 2D,E). F4/80 is an established marker for tissue 
resident macrophages but some infiltrating monocyte-derived macrophages are negative or only weakly immu-
nopositive for F4/8021, 22. In the Bcs1lG/G livers F4/80 staining was reduced suggesting either loss of this marker or 
Kupffer cell depletion. However, the number of IBA1-expressing macrophages was increased in Bcs1lG/G livers and 
normalized by KD at P45 (Fig. 2A,E). In Bcs1lG/G livers the macrophages were larger and protruded out of sinu-
soids, or multiple macrophages surrounded a hepatocyte (Fig. 2A). Neutrophil count was marginally increased in 
the mutant livers (Supplementary Fig. 13).
Gene expression pathway analyses (Supplementary Table 1) indicated changes in four inflammation related 
pathways (Reactome database) in the Bcs1l/G/G mice: formation of fibrin clot, infectious disease, MHC class 
II antigen presentation and phagosomal maturation (p < 0.0003 for all). Furthermore, one fifth of genes that 
were up-regulated more than 3-fold in Bcs1l/G/G mice overlapped with genes that play a role in innate immune 
response (InnateDB23). For example the macrophage marker gene Cd68 was up-regulated 8.5-fold (p < 0.0001) in 
the Bcs1l/G/G mice and downregulated 2.4-fold (p = 0.0046) by KD. Comparison to various published macrophage 
gene expression profiles showed that most of the highly up-regulated genes in Bcs1l/G/G livers were linked to acti-
vated macrophages (Fig. 6A). KD normalized the majority of these gene expression changes towards WT levels.
The expression of the central inflammation and fibrosis-related cytokines, tumor necrosis factor (Tnf) and 
transforming growth factor beta-1 (Tgfb1) was upregulated in Bcs1l/G/G livers, which was in line with the activa-
tion predicted from transcriptomics data (Fig. 6D,E). Of these, Tnf expression was significantly normalized by 
KD (Fig. 6D,E).
KD normalizes perturbed hepatic glutathione metabolism in Bcs1lG/G mice. The expression of 
nine out of seventeen canonical glutathione S-transferase genes detected was up-regulated in Bcs1lG/G mice and 
normalized toward WT levels on KD (Fig. 7A). The most highly up-regulated glutathione transferase gene was 
Gsta1 (87-fold, p < 0.0001, Fig. 7B), which was down-regulated 4.4-fold by KD (p = 0.005). The expression of 
Glutathione synthetase (Gss) was increased 2-fold in Bcs1lG/G mutants (p < 0.001). In line with the gene expres-
sion data, total liver glutathione was increased in the Bcs1l/G/G mice at P45 and normalized to WT levels on KD 
(Fig. 7C).
Discussion
Low-carbohydrate, high-fat diets are an established treatment in drug-resistant epilepsies. Studies in animal mod-
els have suggested that modulation of mitochondria-related functions, including reduced reactive oxygen species 
production, promotion of mitochondrial biogenesis and stimulation of glutathione biosynthesis contribute to 
their beneficial effects in the brain8–10. Here, we demonstrate that KD ameliorated hepatopathy in CIII deficient 
Bcs1l mutant mice at the level of liver histology and liver enzymes, mitochondrial structure and function, and 
gene expression. Marked stellate cell activation and hepatic progenitor cell proliferation24 indicate severe early 
liver injury in these mice despite relatively modest other histological changes. KD feeding reduced fibrosis, num-
ber of apoptotic/necrotic cells, and attenuated stellate cell and hepatic progenitor cell activation, suggesting that 
it either reduced the initial insult (CIII deficiency), affected fibrogenic processes in the liver or induced protective 
mechanisms (e.g. detoxification).
We found structural aberrations in mitochondria, the most striking of which was reduced number and 
increased thickness of cristae, in hepatocytes of Bcs1lG/G mice, and these alterations were prevented by KD. In a 
previous study, KD was shown to normalize overall mitochondrial structure in skeletal muscle in a mouse model 
of mitochondrial myopathy13. Mitochondrial cristae are structurally highly dynamic bioenergetic compartments 
expression (RNA-seq) of two proposed mitochondrial disease markers Fibroblast growth factor 21 (Fgf21) 
and Growth/differentiation factor 15 (Gdf15). n = 9–11/group. The box plot whiskers represent minimum and 
maximum values within the 1.5 interquartile range. (I) Differentially expressed genes in liver transcriptome 
with annotation (GO:0006099) to tricarboxylic acid cycle (TCA cycle). CIII activity and BNGE were done 
from the P95 panel, all other measurements from the P45 panel. *p < 0.05,**p < 0.01; ***p < 0.001. Western 
blot images were cropped for clarity in C and E. The full images are shown in Supplementary Figs. 15 and 16. 
Abbreviations: official gene symbols were used; CI, respiratory chain complex I; CD, control diet; KD, ketogenic 
diet; NDUFA9, NADH:ubiquinone oxidoreductase subunit A9 ; SDHB, succinate dehydrogenase complex iron 
sulfur subunit B; CORE-1, Ubiquinol-cytochrome-c reductase complex core protein 1; RISP, Rieske iron-sulfur 
protein; COX1, Cytochrome c oxidase subunit 1.
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and their shape is linked to RC function25, 26. The reduced number and increased thickness of cristae in hepato-
cytes of Bcs1lG/G mice on CD might be related to disrupted RC complex organization25. Starvation has been shown 
to cause elongation of mitochondria and both starvation and nonglycolytic substrates cause cristae remodeling, 
Figure 5. Liver transcriptome is distinctly altered by the Bcs1l mutation and the diet. (A) Principal component 
analysis of 500 most variable transcripts shows separation of WT and mutant mice (PC1) and partial separation 
of dietary groups and gender (PC2). (B) Heat map of differentially expressed genes. Nineteen genes had 
significant gender-genotype interaction (not shown in the heatmap) (C) A pathway analysis of the gene clusters. 
(D) The most significant transcriptional regulators predicted to drive the observed gene expression changes.
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Figure 6. Ketogenic diet modulates macrophage (MΦ) polarization-related gene expression signatures in 
Bcs1lG/G mice. (A) Liver transcriptomic data overlapping with published MΦ gene expression signatures. 
Expression profiles of in-culture stimulated mouse MΦ (induced from bone marrrow derived monocytes) were 
obtained from Gene expression omnibus (E-GEOD-32690)62. The macrophage populations are named as in the 
original work: M1, IFN-γ + LPS; M2a, IL-4; M2b, IFN-γ + complexed Ig; M2c, Dexamethasone; Mreg, IFN-γ. 
Expression profiles of four thioglycollate stimulated mouse peritoneal MΦ populations (flow cytometry sorted 
for CD115pos, MHC-II, F4/80, SiglecFneg and CD11cpos) were extracted from microarray dataset GSE1590. Liver 
transcriptome data was filtered for q < 0.1 and DESeq2 adjusted fold change > 3 in any of the three pair-wise 
comparison (WT on CD vs KD, WT on CD vs Bcs1lG/G on CD and Bcs1lG/G on CD vs KD). MΦ datasets were 
filtered with the same criteria except that only up-regulated genes were included. (B) The most highly up-
regulated genes overlapping with the profile of thioglycollate stimulated peritoneal MΦ. (C) The most highly 
up-regulated genes overlapping with the profile of M1-type MΦ. (D) Ingenuity Upstream Regulator Analysis 
for cytokines and growth factors predicted to drive observed gene expression changes. (E) Hepatic expression 
of transforming growth factor beta-1 (Tgfb1) and tumor necrosis factor (Tnf) as measured by qPCR. In the box 
plots n = 9–11/group except for Tnf for which n = 6–8/group. The box plot whiskers represent minimum and 
maximum values within the 1.5 interquartile range. *p < 0.05, **p < 0.01, ***p < 0.001.
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including increase in cristae number and reduced width in cultured cells. This process is thought to increase the 
efficiency of ATP production27–29. It is tempting to speculate that the carbohydrate-restricted KD might have 
caused a similar starvation-like or substrate utilization-dependent mitochondrial adaptation in our mouse model, 
leading to normalization of cristae number and morphology.
To investigate if the normalized mitochondrial morphology reflected improved mitochondrial function, we 
measured CIII activity and assessed organization of respiratory chain complexes and supercomplexes in liver 
mitochondria. Indeed, CIII activity was increased by half in the mice on KD, which may have been sufficient to 
ameliorate the liver injury due to CIII dysfunction. Previously, a short term (<24 h) KD administration was also 
shown to increase combined CII and CIII activity in brain cortical mitochondria in a rat mode of traumatic brain 
injury30. Typical markers of mitochondrial mass and biogenesis, such as Ppargc1a expression and citrate synthase 
activity were modestly increased in the mutant mice but not affected by the diet. MtDNA copy number was simi-
lar in all groups and none of the RC subunits analyzed were increased by KD. To the contrary, some RC subunits 
that were increased by the mutation were decreased to WT levels on KD. Transcriptome changes predicted activa-
tion of key regulators of mitochondrial biogenesis, PPAR-α,-γ and -α, PGC-1α and TFAM by KD, but apparently 
this transcriptional response did not result in increased mitochondrial mass. Ketone bodies have been shown 
to restore complex I stability and activity in a complex I deficient cell line31. Therefore, we assessed RC complex 
and supercomplex amount in liver mitochondria of the mice using BNGE. Despite that KD did not increase 
total amount of RISP in whole tissue lysate, more fully assembled CIII was found in isolated mitochondria from 
Bcs1lG/G mice on KD than on CD. This finding suggests improved CIII assembly or stability and offers an explana-
tion for the increased CIII activity on KD. Dietary fat composition has been shown to affect phospholipid com-
position of mitochondrial membranes32 and affect respiratory chain supercomplex assembly and function33, 34. 
Figure 7. Liver transcriptome analysis reveals perturbed glutathione metabolism in Bcs1lG/G mice and its 
normalization by ketogenic diet. (A) Differentially expressed genes with annotation to glutathione metabolism 
and their subannotation to different branches of glutathione metabolism [glutathione transferase activity 
GO:0004364, glutathione peroxidase activity GO:0004602, glutathione-mediated detoxification (source: 
HumanCyc), glutathione biosynthesis (HumanCyc)]. (B) Hepatic mRNA level (RNA-seq) of Gsta1. (C) Hepatic 
total glutathione level. The results were normalized to total protein concentration and approximate glutathione 
content per wet weight is presented. The box plot whiskers represent minimum and maximum values within the 
1.5 interquartile range. **p < 0.01; ***p < 0.001. All results are from the postnatal day 45 age.
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Our KD contained a high proportion of polyunsaturated long-chain fatty acids, which may have had an effect on 
mitochondrial membrane composition and, subsequently, on CIII and supercomplex composition in our model.
Previously, a ketogenic diet, with a more extreme protein restriction than our formulation (see later dis-
cussion), decreased liver mitochondrial mass likely by up-regulating gene and protein expression of starvation 
induced mitophagy factor, BNIP335. We observed that KD increased hepatic Bnip3 expression in both genotypes. 
The Bcs1lG/G mice on CD had decreased Bnip3 transcript levels compared to WT mice along with reduced mRNA 
levels of the autophagy regulators Atg3 and Atg536. Taken together, our results indicate that the increased CIII 
activity and the beneficial effect of KD were not due to increased liver mitochondrial mass but likely to other 
adaptive mitochondrial responses such as improved mitochondrial quality control via autophagy and improved 
maintenance of cristae structure and RC function, including improved CIII assembly and activity.
Hepatic immune cells, including Kupffer cells and infiltrating monocyte-derived macrophages are key pro- 
and anti-fibrotic regulators37. The Bcs1lG/G mice had substantially altered liver macrophage populations as shown 
by immunostainings and macrophage-related gene expression patterns, and these were clearly modulated by the 
diet. KD also reduced the number of ceroid-lipofuscin-laden macrophages in Bcs1lG/G livers, likely reflecting a 
reduced need for clearance of cellular debris due to reduced cell death. A reduced number of F4/80 positive mac-
rophages, but increased total macrophage count, has been shown previously in the acute phase of liver injury21, 22. 
These studies also identified the weakly F4/80-immunopositive subsets as infiltrating monocyte-derived mac-
rophages. In contrast, the number of IBA1, CD68 and galectin-3 positive macrophages increases upon liver 
injury38, 39. We observed depletion of F4/80-expressing macrophages in Bcs1lG/G livers but an increased number of 
IBA1-positive macrophages, the latter of which was reduced on KD. Expression of galectin-3 (Lgals3) and Cd68 
was highly induced in Bcs1lG/G on CD and significantly less so on KD. Of interest, macrophage polarization and 
their inflammatory properties can be modified by mitochondrial function40. The M1, or classically activated, 
subset of macrophages is mainly relying on anaerobic glycolysis whereas the M2, or alternative activated subset, 
is dependent on oxidative phosphorylation. The M2-like subsets are particularly important in tissue repair and 
resolution of inflammation40. Interestingly, mice with global CI subunit Ndufs4 knock-out have systemic inflam-
mation and osteopetrosis due to shift in macrophage polarization and osteoclast differentiation41.
In our model, components of the KD may have affected liver disease progression via mechanisms unrelated 
to energy metabolism. Docosahexanoid acid, a long-chain polyunsaturated n-3 fatty acid, can suppress mito-
chondrial membrane transition pore opening, a key event leading to apoptosis32. Indeed, we found significantly 
less dying hepatocytes in Bcs1lG/G mice on KD. Certain long-chain fatty acids and their derivatives are ligands for 
PPAR-α and -γ42. In our KD-fed mice, the expression of several PPAR-α- and PPAR-γ-regulated genes was altered 
in the liver transcriptome, suggesting that diet-dependent modulation of ligand binding to PPAR-α and -γ may 
have played a role. Other putative mediators are HCAR2, a receptor for the major ketone body β-hydroxybyturate, 
expressed in white adipose tissue and some immune cells including macrophages43, 44 and FFAR4 (free fatty acid 
receptor 4), the activation of which modulates macrophage polarization34, 35. FFAR4 is activated by long-chain 
fatty acids and our KD formulation provided 2.8-fold more α-linolenic acid (C18:3 n-3) relative to energy content 
than the CD. The putative role of these receptors in mediating the effect of the KD should be further studied by 
administering ketone esters or the respective receptor agonists.
Induction of liver detoxification genes was minimal in Bcs1lG/G mice except for glutathione S-transferase 
(GST) genes. GSTs detoxify a variety of compounds, including oxidative stress-induced metabolites such as 
4-hydroxynonenal45. Some GSTs also possess peroxidase activity, and as such are antioxidant enzymes. In addi-
tion, the majority of GST genes contain antioxidant response element in their promoter region and are regula-
tory targets of NRF2, the major oxidative stress responsive transcription factor. The expression of several GST 
genes was highly induced in the liver of Bcs1l mice and this induction was partially reversed by KD feeding. 
Interestingly, the gene expression profile of GSTs in Bcs1lG/G mice showed similar induction of cytoplasmic GST 
genes as observed in the mouse liver when NRF2 pathway is over activated46. As for oxidative stress, we found 
up-regulated expression of three genes encoding antioxidant enzymes (Gpx3, Gpx4 and Nqo1) in the liver of 
Bcs1lG/G mice as well as of glutathione synthetase. Intriguingly, catalase expression was downregulated 1.8 fold 
(data not shown). KD had no effect on the expression of these genes. In line with the gene expression data liver 
total glutathione content was increased in Bcs1l mice on CD but reduced to WT levels on KD. We interpret 
these results so that there was reduced need for detoxification and less cellular glutathione synthesized when the 
Bcs1lG/G mice were on KD.
A small retrospective study found KD treatment effective and relatively safe in respiratory chain defects 
related childhood epilepsy9. However, a KD intervention trial in mitochondrial myopathy patients had to be 
prematurely discontinued due to muscle pain and selective muscle fiber damage47. We found that Bcs1lG/G mice 
showed eventual intolerance to the diet manifesting as more rapid behavioral decline after eleven weeks of feed-
ing. Depleted glycogen stores might have led to an exacerbated energy crisis. However, blood glucose and lactate 
values at sacrificing time were not significantly different on the two diets. Common rodent KD formulations con-
tain only 5E% protein and provide inadequate choline and methionine intake48, 49. These KDs cause robust ketosis 
but also hinder growth of the mice and in some studies have caused adverse liver effects including steatosis48–50. 
KD formulations with higher protein content are nutritionally more suitable but reduce the ketogenic effect in 
rodents51. In line with this we observed only transient ketosis in WT mice while the Bcs1l mice remained ketotic 
during the entire intervention. The KD-fed mice had similar weight gain as those mice on CD and no overt signs 
of protein malnutrition (weight loss or reduced plasma total protein), which is in line with findings from studies 
using KD with similar protein content (~9E%)48, 52. Liver fat content was increased on KD in both genotypes but 
according to triglyceride measurements this increase did not fulfill the criteria of steatosis (50 mg/g, 57µMol/g 
triglycerides)53. Our previous study showed a starvation-like condition and high levels amino acids in liver of 
Bcs1l mice at end-stage disease54. In this study, metabolomics analysis showed similar elevation of plasma amino 
acids in Bcs1lG/G mice on both diets, which suggests that the probable catabolic state was not exacerbated by KD.
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The present study shows that KD may have therapeutic potential in mitochondrial hepatopathies, currently 
incurable disorders. Further studies in animal models, and eventually in patients, should be designed to elaborate 
the effect of ketogenic diets on mitochondrial function and inflammatory processes in the context of respiratory 
chain deficiency.
Methods
Animal experiments. Congenic Bcs1lc.232A>G mice7, 55 were maintained by crossing heterozygotes to wild-
type C57BL/6JCrl mice. The survival of the Bcs1lc.232A>G homozygous (Bcs1lG/G) mice in this background is on 
average 200 days. The animal ethics committee of the State Provincial Office of Southern Finland approved the 
animal experiments (permit numbers ESAVI-2010-07284/Ym-23 and ESAVI/6142/04.10.07/2014) and the exper-
iments were carried out in accordance with the permits, Laboratory Animal Centre of the University of Helsinki 
practices and the Federation of Laboratory Animal Science Associations (FELASA) guidelines.
Litters were randomized to CD or KD. The CD (Teklad 2018, Harlan) was a cereal and soy-based rodent 
chow providing 18% of energy (E%) as fat, 58E% as carbohydrates and 24E% as protein. The KD (TD.96355, 
Harlan) was based on vegetable shortening, corn oil and casein, providing 90.5E% fat (1/3 as polyunsaturated 
fatty acids; 30.8 E% linoleic acid and 2.5E% α-linolenic acid), 0.4E% carbohydrates and 9.1 E% protein. Both 
diets provided approximately the same amount of choline (~8.5 mg/100 kJ) and methionine (~30 mg/100 kJ). The 
KD-chow was introduced into the cages from one week of age. From weaning on, the pups randomized to KD 
received ad libitum KD only. The CD and KD groups were sacrificed at postnatal age 40–45 days (which we refer 
as P45-group, n = 11–14/group) or P90-P114 (P95-group, n = 8–9/group). One cohort was followed until deteri-
oration (P114-P173, n = 4/group). Both genders were used and for each homozygote a wild-type or heterozygote 
control was included. These control animals are referred to as wild-type (WT). The heterozygous mice are pheno-
typically wild-type7. Significant gender differences were not observed if not otherwise stated.
Sample collection. Blood glucose, lactate and ketone concentrations were measured from tail tip blood 
under brief isoflurane anesthesia. For other samples, the mice were sacrificed with carbon dioxide inhalation and 
cervical dislocation or, for blood collection via cardiac puncture, injected with a lethal dose of pentobarbital. The 
mice were not fasted prior to sample collection due to the hypoglycemia associated with the phenotype of the 
homozygotes. All samples were collected at the same time of the day during the light period of the mice. Blood 
was collected by cardiac puncture into Li-heparin tubes and plasma was separated and stored at −80 °C. Tissues 
were collected into 10% histology-grade formalin or snap frozen in liquid nitrogen and stored at −80 °C.
Histology and immunostaining. Liver sections were processed and stained with standard methods to assess 
general histology (hematoxylin-eosin), glycogen content (periodic acid-Shiff, PAS), neutral fat content (Oil Red 
O), fibrosis (Sirius Red) and ultrastructure (electron microscopy). Primary antibodies used in immunohistochem-
ical staining are listed in Supplementary Table 3. Vectastain Elite peroxidase reagents (Vector Laboratories) were 
used for detection. Apoptotic and necrotic cells were counted from H&E-stained sections based on characteristic 
morphological features such as condensed hypereosinophilic cytoplasm, cell swelling and condensed, fragmented 
or dissolved nucleus according to published guidelines56. All quantifications were performed in random-blind 
fashion. Technical details of the image analyses are described in Supplementary Materials and Methods.
Electron microscopy. Approximately 1 mm3 pieces of liver were fixed in 1.5% glutaraldehyde, 1.5% par-
aformaldehyde in 0.1 M Sörensen buffer pH 7.2, and processed for electron microscopy according to standard 
methods. Area, cristae number and thickness, and the shape of hepatocyte mitochondria were determined manu-
ally from images in Adobe Photoshop CS5. Cross sectional area was determined by manually selecting the longest 
and shortest axis of each mitochondria. Approximately 100 different hepatocytes were chosen at random loca-
tions and layers throughout at least 10 different specimen preparations. About five randomly chosen mitochon-
dria per hepatocyte were measured, giving a total of approximately 500 mitochondria per independent sample.
Clinical chemistry and plasma metabolomics. Clinical chemistry parameters were measured from 
plasma samples using Siemens ADVIA1650 analyzer. Targeted plasma metabolomics (101 metabolites) was per-
formed using an ACQUITY UPLC-MS/MS system as previously described57.
Lipid analyses. Liver triglycerides were measured as enzymatic release of glycerol after methanol-chloroform 
extraction of lipids as previously described58. The same lipid extracts were used to measure non-esterified fatty 
acids by an enzymatic colorimetric assay (Roche Diagnostics).
Protein analysis. Western blot analyses were used to quantify the amount of proteins in tissue lysates. 
The antibodies used are shown in Supplementary Table 3 and technical details in Supplementary Materials and 
Methods. For the quantifications, 28 independent samples were run in a random order. For representative blots, 
pooled lysates of 6–8 samples were used. The data were normalized to total protein transferred onto membrane 
as visualized and quantified by Stain-free imaging technology (Bio-Rad). Digitonin-solubilized respiratory chain 
complexes and supercomplexes were assessed with BNGE and immunoblotting as described earlier55 except that 
Bio-Rad tank electroblotting apparatus and 1-hour transfer time was used. The BNGE analysis was performed 
twice on four mice per group with consistent results.
Enzyme activity assays. CIII activity in isolated mitochondria was measured with decylubiquinol as sub-
strate and cytochrome c as final electron acceptor in a spectrophotometric assay7. Citrate synthase activity was 
measured with a commercial kit (Sigma-Aldrich Cat.no CS0720).
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RNA sequencing (RNA-seq) and quantitative PCR (qPCR). For library preparation, sequencing and 
data pre-processing we followed a published protocol59 except that 10 ng total RNA from liver tissue rather than 
single cells were used. Differential gene expression analysis and read count normalization were performed with 
DESeq2 package for R60. For gene set enrichment analyses and heat maps, the gene lists were filtered for absolute 
DESeq2 shrunken fold change of more than 1.4 and false discovery rate corrected p-value less than 0.1 if not 
otherwise stated. The enriched gene sets were retrieved from ConsensusPathDB61. Ingenuity Upstream Regulator 
Analysis (Qiagen) was used to predict activated or inhibited transcription regulators, cytokines and growth fac-
tors. Public microarray gene expression data sets were obtained from the Gene Expression Omnibus and ana-
lyzed using GEO2R (both by NCBI) (E-GEOD-32690)62 or from the ImmGen database63 as a pre-analyzed data 
set (GSE1590)63. The expression of 45 genes was verified by qPCR (Supplementary Fig. 12 and Supplementary 
Materials and Methods).
Mitochondrial DNA (mtDNA) copy number quantitation. mtDNA copy number in total liver 
genomic DNA was determined by measuring the relative amount of a mitochondrial (MT-Rnr1) and a nuclear 
gene (Actb) with qPCR.
Liver total glutathione was assessed with GSH-Glo™ Glutathione kit (Promega).
Statistics (excluding transcriptomics and metabolomics). As a main strategy to test whether the 
groups differed, one-way ANOVA was performed. Significant ANOVA results were followed by three planned 
comparisons: 1) WT on CD vs WT on KD, 2) WT on CD vs Bcs1lG/G on CD and 3) Bcs1lG/G on CD vs Bcs1lG/G 
on KD. If the normality assumption of ANOVA was violated, Kruskal-Wallis test and Mann-Whitney U-tests 
were used instead. Two-way ANOVA was used where age of the mice needed to be included in the analysis. The 
Bonferroni correction was applied to the two-way ANOVA results.
Further information is provided in Supplementary Materials and Methods.
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